Protective and disease-enhancing immune responses to respiratory syncytial virus

Journal of Infectious Diseases

Volumn 171, Issue 1, 1995, Pages 1-7

  Anderson, Larry J ^a,b   Heilman, Carole A ^a,b  

^a Centersfor Disease Control and Prevention ^*  (Georgia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; ATTENUATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; LOWER RESPIRATORY TRACT INFECTION; MEMORY CELL; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION; VIRUS SHEDDING;

ANIMAL; ANTIBODIES, VIRAL; HUMAN; IMMUNITY, ACTIVE; IMMUNITY, CELLULAR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0028851339     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.1.1     Document Type: Article

References (51)

1. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiralory-syn-cytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979;300:530-4
2. Hall CB, Walsh EE, Long CE. Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163:693-8
3. Wagner DK, Muelenaer P, Henderson FW, et al. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. J Clin Microbiol 1989;27:589-92
4. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylaxis with respiratory syncytial virus immune globulin in high risk children. N Engl J Med 1993;329:1524-30
5. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985;55:517-20
6. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunopro-phylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985;3:193-206
7. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-15
8. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal anti body and respiratory syncytial virus infection in infancy. J Med Virol 1981;7:263-71
9. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1981:134:21 1-7
10. Crowe JE Jr. Murphy BR, Chanock RM, Williamson RA. Barbas CR III, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91:1386-90
11. Mills JV, Van Kirk JE, Wright PF, Chanock RM. Experimental respiratory syncytial virus infection of adults. J Immunol 1971; 107:123-30
12. Welliver RC, Wong DT. Sun M, Middleton E Jr. Vaughan RS. Ogra PL. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 1981;305:841-6
13. Isaacs D, Bangham CRM, McMichael AJ. Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. Lancet 1987;2:769-71
14. Cherrie AH, Anderson K, Wertz GW, Openshaw PJM. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and lb proteins of respiratory syncytial virus. J Virol 1992;66:2102-10
15. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77-81
16. Johnson PR, Collins PL. The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences. J Gen Virol 1988:69:2901-6
17. Johnson PR, Collins PL. The IB (NS2), IC (NSI) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA. J Gen Virol 1989;70:1539-47
18. Collins PL, Olmsted RA, Johnson PR. The small hydrophobic protein of respiratory syncytial virus: comparison between antigenic subgroups A and B. J Gen Virol 1990;71:1571-6
19. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991;65:5425-34
20. Cane PA, Matthews DA, Pringle CR. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. J Gen Virol 1991;72:2091-6
21. Cane PA, Pringle CR. Respiratory syncytial virus heterogeneity during an epidemic: analysis by limited nucleotide sequencing (SH) and restriction mapping (N gene). J Gen Virol 1991;72:349-57
22. Anderson LJ, Hendry RM, Pierik LT, Tsou C, McIntosh K, Multicenter study of strains of respiratory syncytial virus. J Infect Dis 1991;163:687-92
23. Mufson MA, Belshe RB, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol 1987;25:1535-9
24. Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162:1283-90
25. Graham BS, Bunton LA, Wright PF, Karzon DT. Role ofT lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-33
26. Graham BS, Bunton LA, Rowland J. Wright PF, Karzon DT. Respiratory syncytial virus infection in anti-/z-treated mice. J Virol 1991;65:4936-42
27. Stott EJ, Taylor G, Ball LA, et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 1987;61:3855-61
28. Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 1991;65:1634-7
29. Kulkarni AB, Connors M, Firestone CY, Morse HC III, Murphy BR. The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice. J Virol 1993:67:1044-9
30. Roberts SR, Lichtenstein D, Ball LA, Wertz GW. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 1994;68:4538-46
31. Alwan WH, Record IM, Openshaw PJM. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol 1993:150:521 1-8
32. Alwan WH, Kozlowska WJ, Openshaw PJM. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 1994;179:81-9
33. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151:2032-40
34. Kim HW, Leikin SL, Arrobio J, Brandt CD. Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976;10:75-8
35. Prince GA, Jenson AB, Hemming VG, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986:57:721-8
36. Murphy BR, Prince GA, Walsh EE. et al. Dissociation between serumneutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986:24:197-202
37. Connors M, Collins PL, Firestone CY, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992;10:475-84
38. Connors M. Klulkarni AB. Firestone CY, et al. Pulmonary histopathol-ogy induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion ofCD4+ T cells. J Virol 1992;66:7444-51
39. Wierenga EA, Snoek M, Jansen HM, Bos JD, van Lier RAW, Kapsen-berg ML. Human atopen-specific types I and 2 helper cell clones. J Immunol 1991;147:2942-9
40. Robinson DS, Hamid Q, Ying S, et al. Predominant Th2-like bron-choalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304
41. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC III. Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin (1L-4) and IL-I0. J Virol 1994;68:5321-5
42. Kakuk TJ, Soike K, Brideau RJ, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993;167:553-61
43. Lapin CD. Hiatt PW, Langston C, Mason E, Piedra PT. A lamb model for human respiratory syncytial virus infection. Pediatr Pulmonol 1993;15:151-6
44. Crowe JE Jr. Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994;12:783-90
45. Crowe JE Jr, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994:12:691-700
46. Randolph VB, Kandis M, Stemler-Higgins P, etal. Attenuated temperature sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res 1994;33:241-59
47. Collins PL, Mink MA, Hill MG III, Camargo E, Grosfeld H, Stec DS. Rescue of a 7502-nucleotide (49.3% full-length) synthetic analog of respiratory syncytial virus genomic RNA. Virology 1992; 195:252-6
48. Qingzhong Y. Hardy R. Wertz GW. (W19-5) establishment of a reverse genetic analysis system for human respiratory syncytial (RS) virus [abstract]. In: Program and abstracts of the 13th annual meeting of the American Society for Virology, Madison. Wl: American Society for Virology. 1994:175
49. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune response to subsequent natural infection in children. J Infect Dis 1993;168:1024-9
50. Walsh EE, Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 1994;170:345-50
51. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 1991;185:749-57